Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announced that its Phase II in‑vitro study with the U.S. Army Institute of Surgical Research validated a no‑wash 3 % DMSO cryopreservation protocol, delivering a 94% mean post‑thaw platelet recovery. The protocol also outperformed wash‑based and trehalose approaches on clot strength and platelet‑receptor retention. The study, the largest of its kind with 20 donors, showed frozen platelets meeting or exceeding fresh‑platelet quality standards. Vitrafy now aims for FDA device registration in the first half of FY 2027 to commercialise the technology.
Connexion Mobility Acquires Hallam Road Automotive to Diversify Earnings Base
Connexion Mobility (ASX: CXZ) signed a definitive agreement to acquire Melbourne‑based Hallam Road Automotive for a total consideration of about AUD5 million (roughly US$3.3 million). The deal includes an upfront cash payment of AUD4 million (≈US$2.6 million) and a performance‑based earn‑out of AUD1 million (≈US$0.66 million),...
TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
TrivarX announced a partnership with specialist CRO Beyond Drug Development to drive the Phase 1 safety trial of its Stabl‑Im oncology imaging platform. Beyond will handle protocol finalisation, regulatory documentation and site selection as TrivarX prepares to dose healthy volunteers in...
KALiNA Power Welcomes New Canadian Regulatory Framework on Carbon Management and Emissions
KALiNA Power’s subsidiary, KALiNA Distributed Power, will benefit from a new Canada‑Alberta regulatory framework that harmonises carbon‑management policies and introduces 75 million tonnes of carbon contracts for difference (CFDs) to support CCS projects between 2030 and 2040. The agreement suspends Alberta’s...
AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings
AFT Pharmaceuticals reported FY26 operating revenue of $254.7 million (≈$168 million USD), a 22% increase, and net profit of $14.1 million (≈$9.3 million USD). International sales and royalties surged 66% to $28.5 million (≈$19 million USD), driven by stronger offshore hubs and a 41% jump in...
Advance Metals Moves Towards Full Ownership of Myrtleford and Beaufort Gold Projects
Advance Metals (ASX: AVM) has agreed to acquire the remaining 20% interest in the Myrtleford and Beaufort gold projects in Victoria, bringing its ownership to 100%. The deal adds $1.02 million to the original $3.05 million consideration, raising the total payment to...
Comet Ridge Softens Terms and Extends Timelines for Mahalo Acquisition
Comet Ridge has renegotiated its deal to buy a 42.86% stake in the Mahalo Gas Project, cutting the upfront cash component to roughly $12 million USD and adding a $6.6 million USD share issue for Santos. The agreement now includes up to...
Novatti Group's UNSW Alipay Integration Surpasses Revenue and Transaction Volume Expectations
Novatti Group’s Alipay integration at the University of New South Wales (UNSW) has delivered roughly $22 million USD in gross transaction value and $0.33 million USD in revenue through April 2026, surpassing the company’s expectations. The rollout, which went live in October 2025, makes...
Barton Gold Extends Near-Surface Mineralisation at Challenger Project
Barton Gold announced new assay results from its Challenger gold project in South Australia, confirming near‑surface mineralisation that could support additional open‑pit mines adjacent to the Central Gawler Mill. The drilling, covering the Challenger South‑Southwest deposit and the Challenger 3 target,...
Alcidion Expands Patient Flow Business with Kyra Acquisition From Telstra Health
Alcidion Group announced the purchase of Telstra Health’s Kyra Patient Flow suite for roughly $2 million in cash, adding an estimated $2.4 million of FY26 revenue and a 2.7× EBITDA multiple. The deal brings 33 long‑standing customers—only two of which already use...
Algorae Pharmaceuticals Expands AI Drug Combination Pipeline with Multi-Anchor AOS2 Program
Algorae Pharmaceuticals announced the completion of the prediction‑generation phase of its multi‑anchor drug‑combination program, leveraging the AlgoraeOS v2 (AOS2) AI platform. The effort produced in‑silico synergy forecasts for 18 anchor drugs across thousands of approved and investigational compounds, covering more...
EOS Advances MARSS Acquisition with Revised Terms as Counter-Drone Orders Surge
Australian defense tech group Electro Optic Systems (EOS) moved forward with its planned acquisition of UK‑based MARSS, revising the earnout cap to €140 m ($153 m) and securing a $36 m cash payment from a A$70 m ($46 m) loan. MARSS announced new orders totaling...
Clean TeQ Water Wins Rasp Mine Tailings Dewatering Plant Contract From Broken Hill Mines
Clean TeQ Water has been awarded a design‑and‑construct contract by Broken Hill Operations to build a 750,000‑tonne‑per‑year ATA tailings dewatering plant at the Rasp Mine in New South Wales. The plant will replace higher‑cost solar drying, enabling the mine to...
Racura Oncology Advances CPACS Trial to Next Dose Level
Racura Oncology (ASX:RAC) received Safety Review Committee clearance to double the RC220 dose from 40 mg/m² to 80 mg/m² for Cohort 2 of its CPAPS Phase 1 trial, pairing the drug with doxorubicin. The first three Cohort 1 patients showed no dose‑limiting toxicities, and all...
Archer Materials Advances Biosensor Prototype Toward Preclinical Validation
Archer Materials announced that its alpha Biosensor prototype, built on its Biochip platform, has reached clinical‑grade potassium‑sensing accuracy. The company is now engineering a beta prototype designed for pre‑clinical validation and eventual patient trials, with the first beta system expected...